Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.
Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
SALT LAKE CITY - Recursion Pharmaceuticals (NASDAQ:RXRX) announced Monday that its investigational drug REC-4881 demonstrated significant polyp reduction in patients with familial adenomatous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback